Redeye: Acarix Q4 2023 - Soft ending to 2023 but gearing up for 202
Redeye updates its outlook on Acarix following its year-end report 2023. Anticipating an eventful year head, we make minor adjustments to our forecasts and valuation.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/